Platelet activation in patients with advanced gastric cancer

Osada, Joanna; Rusak, Małgorzata; Kamocki, Zbigniew; Mi, Dabrowska; Kędra, Bogusław

doi:10.4149/neo_2010_02_145

Cited by 55 publications

(52 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Assessment of the MPV in patients with malignant tumours has recently attracted substantial interest even though some results have been controversial. For instance, previous studies have reported that the MPV was higher in patients with gastric cancer than in control patients and that the MPV/PC (platelet count) ratio was meaningfully increased in patients with hepatocellular carcinoma [29, 30]. In addition, published research has reported a significant correlation between high MPV and advanced cancer, such as gastric cancer [16], hepatocellular carcinoma [30], endometrial cancer [15], breast cancer [31], and colon cancer [32].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer

Gao

Zhang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

The aim of the present study was to investigate the prognostic value of the combination of preoperative platelet count (PLT) and mean platelet volume (MPV) in patients with primary operable non-small cell lung cancer (NSCLC). We retrospectively analysed data from 546 patients with NSCLC who underwent complete resection at our institution from 2006 to 2010. Patients’ clinical characteristics and laboratory test data at initial diagnosis were collected. Both preoperative PLT and MPV (COP-MPV) were calculated on the basis of the data obtained using the recommended cut-off values of 300 × 109 L−1 and 11.0 fL, respectively. Patients with both an elevated PLT (≥300× 109 L−1) and a decreased MPV (<11.0 fL) were assigned a score of 2, and patients showing one or neither were allocated a score of 1 or 0, respectively. Multivariate analysis of the 9 clinical laboratory variables selected by univariate analysis revealed that preoperative COP-MPV was a significantly independent prognostic factor for overall survival (OS) (hazard ratio, 1.775; 95% confidence interval, 1.500–2.101; P< 0.001) and disease-free survival (DFS) (hazard ratio, 1.719; 95% confidence interval, 1.454–2.033; P< 0.001). In subgroup analyses for tumour pathological stage (I/II/IIIA) patients, we found that the level of COP-MPV was significantly associated with OS and DFS in each subgroup (P< 0.001, P< 0.001, P<0.001 for OS and P<0.001, P< 0.001, P=0.001 for DFS, respectively). In conclusion, the preoperative COP-MPV is a promising predictor of postoperative survival in patients with NSCLC and could classify these patients into three independent groups before surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer

Gao

Zhang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Recent studies found that MPV could be used to predict the onset of venous thromboembolism and arterial thrombosis (Braekkan et al, 2010). Furthermore, MPV may be a diagnosis marker in hepatocellular carcinoma, pancreatic adenocarcinoma, and gastric cancer (Osada et al, 2010;Karaman et al, 2011;Kurt et al, 2012).…”

Section: * Xi-shan Wang 1 *mentioning

confidence: 99%

Elevated Mean Platelet Volume is Associated with Presence of Colon Cancer

Liu²,

Jiang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Colon cancer is the second most common cancer in developed countries. Activated platelets play a key role in inflammation and atherothrombosis, with mean platelet volume (MPV) is an early marker of platelet activation. The aim of the study was to clarify the relevance of MPV in patients with colon cancer. Materials and Methods: We measured MPV levels in 128 patients with colon cancer before and after surgery, and 128 controls matched for age, gender, body mass index (BMI) and smoking status. The odds ratios (ORs) and 95% confidence intervals (CIs) for colon cancer were calculated using multivariate logistic regression analyses across MPV quartiles. Results: Patients with colon cancer had higher MPV compared with controls. Surgical tumor resection resulted in a significant decrease in MPV levels (11.4 fL vs 10.7 fL; p<0.001). A positive correlation between MPV and tumor-nodule-metastases (TNM) stage was found. Furthermore, after adjusting for other risk factors, the ORs (95%CIs) for colon cancer according to MPV quartiles were 1.000, 2.238 (1.014-4.943), 3.410 (1.528-7.613), and 5.379 (2.372-12.198), respectively. Conclusions: The findings show that patients with colon cancer have higher MPV levels compared with controls, and these are reduced after surgery. In addition, MPV was found to be independently associated with the presence of colon cancer. Further studies are warranted to assess the utility of MPV as a novel diagnostic screening tool for colon cancer.

show abstract

“…In cancer patients, sCD40L is more likely derived from activated platelets than from T-cells [15]; therefore, sCD40L can affect cancer development and progression by inducing thrombotic reactions and releasing angiogenesis-associated cytokines. This idea is supported by evidence that cancer patients, including those with pancreatic ductal adenocarcinoma (PDAC), have significant platelet activation [16-18]. Widespread expression of CD40 in human carcinomas also supports the role of this ligand in cancer pathogenesis [19].…”

Section: Introductionmentioning

confidence: 97%

Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma

Chung

Lim

2014

Journal of Translational Medicine

View full text Add to dashboard Cite

BackgroundCD40-CD40 ligand (CD40L) interaction is considered to contribute to the promotion of prothrombotic responses and production of angiogenesis-associated factor in addition to adaptive immune responses. Recently, the role of soluble CD40L (sCD40L) has gained interest in cancer, although its exact functions remain unknown. This study evaluated the clinical significance of sCD40L in patients with pancreatic ductal adenocarcinoma (PDAC) and validated its utility as a PDAC diagnostic and prognostic biomarker.MethodsSerum sCD40L levels were measured by chemiluminescent immunoassay and compared among normal, chronic pancreatitis (CP, high-risk), and PDAC group in both training (n = 25 per group) and independent validation (n = 30, 30, and 55, respectively) datasets through one-way ANOVA test with the post-hoc Bonferroni method. To evaluate the diagnostic potential of serum sCD40L for PDAC, receiver operating characteristic (ROC) curves were generated and logistic regression analysis was conducted. To investigate the sCD40L-assoicated cytokines/chemokines in PDAC, cytokines/chemokines levels were analyzed by a MILLIPLEX MAP Human Cytokine/Chemokine Kit. To assess the prognostic potentials of sCD40L, Kaplan-Meier survival curve and Cox proportional-hazards regression analysis were applied.ResultsSerum sCD40L levels were significantly higher in PDAC group compared with non-cancer groups in both training (p < 0.05) and validation (p < 0.05) datasets. Clinically, serum sCD40L closely correlated with unresectability (γs = 0.342, p = 0.011) and distant metastasis (γs = 0.294, p = 0.030) of PDAC. ROC curve and logistic regression analysis demonstrated the remarkable predictive potentials of serum sCD40L for PDAC (80.0% sensitivity and 85.5% specificity at cut-off point, 0.45; logistic regression), superior to those of CA19-9 and CEA. According to cytokines/chemokines assay, serum sCD40L levels were closely correlated with serum levels of pro-angiogenic cytokines (EGF, VEGF, IL-8) and immunosuppressive cytokines (IL-6, IL-10, IL-1RA). Kaplan-Meier survival analysis demonstrated patients with high-serum sCD40L (> 35,000 ng/ml) had a poorer prognosis than those with low-serum sCD40L (log-rank, p = 0.015). Multivariate Cox regression analysis yielded a hazard ratio of 2.509 (95% CI, 1.038–6.067, p = 0.041) for mortality in the high-serum sCD40L group.ConclusionsSerum sCD40L is correlated with immunosuppression and angiogenesis in PDAC carcinogenesis/progression, and is a promising diagnostic and prognostic biomarker for PDAC superior to CA19-9 and CEA.

show abstract

Platelet activation in patients with advanced gastric cancer

Cited by 55 publications

References 13 publications

Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer

Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer

Elevated Mean Platelet Volume is Associated with Presence of Colon Cancer

Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About